Table 2.

Comparison of mortality rates between direct-acting antiviral agent (DAA) treated patients and DAA untreated patients

DAA untreated versus treated	Patients, n	Deaths, n	Person-years	Mortality-rate per 100 person-years (95% CI)	Crude rate (95% CI)	P value
Cirrhosis patients
Overall - DAA untreated	4,120	1,310	9,234.75	14.19 (13.42–14.95)	—
Overall - DAA treated	4,120	480	10,531.15	4.56 (4.15–4.97)	0.32 (0.29–0.35)	<0.001
Female
DAA untreated	1,501	420	3,431.03	12.24 (11.07–13.41)	—
DAA treated	1,515	148	3,888.59	3.81 (3.19–4.42)	0.31 (0.25–0.37)	<0.001
Male
DAA untreated	2,619	890	5,803.72	15.33 (14.33–16.34)	—
DAA treated	2,605	332	6,642.55	5.00 (4.46–5.54)	0.33 (0.28–0.37)	<0.001
Non dual eligibles^a
DAA untreated	1,350	404	2,984.10	13.54 (12.22 – 14.86)	—
DAA treated	1,388	159	3,517.55	4.52 (3.82–5.22)	0.33 (0.27–0.40)	<0.001
Dual eligibles^b
DAA untreated	2,770	906	6,250.65	14.49 (13.55–15.44)	—
DAA treated	2,732	321	7,013.60	4.58 (4.08–5.08)	0.32 (0.28–0.36)	<0.001
Non-cirrhosis patients
Overall - DAA untreated	21,619	2,955	61,587.84	4.80 (4.63–4.97)	—
Overall - DAA treated	21,619	912	55,792.87	1.63 (1.53–1.74)	0.34 (0.32–0.37)	<0.001
Females
DAA untreated	8,995	978	26,253.96	3.72 (3.49–3.96)	—
DAA treated	8,994	291	23,322.38	1.25 (1.10–1.39)	0.33 (0.29–0.38)	<0.001
Males
DAA untreated	12,624	1,977	35,333.88	5.59 (5.35–5.84)	—
DAA treated	12,625	621	32,466.57	1.91 (1.76–2.06)	0.34 (0.31–0.37)	<0.001
Non dual eligibles^a
DAA untreated	6,318	787	17,082.09	4.61 (4.28–4.93)	—
DAA treated	6,437	239	16,648.38	1.44 (1.25–1.62)	0.31 (0.27–0.36)	<0.001
Dual eligibles^b
DAA untreated	15,301	2,168	44,504.75	4.87 (4.67–5.08)	—
DAA treated	15,182	673	39,140.58	1.72 (1.59–1.85)	0.35 (0.32–0.38)	<0.001

Abbreviations: CI, Confidence intervals; DAA, Direct-acting antiviral drug

Non dual eligibles are eligible for Medicare only

Dual eligibles are eligible for Medicare and Medicaid